Vivian Fonseca
Biographic Data
| ID | 5545007 |
|---|---|
| NAME | Vivian Fonseca |
| GIVEN NAMES | Vivian |
| FAMILY NAME | Fonseca |
| SIGNATURE | FONSECA V |
| AFFILIATIONS | Section of Endocrinology, Tulane University Health Sciences Center, New Orleans |
| ORCID | 0000-0002-3381-7151 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2023 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Cost-effectiveness of iGlarLixi vs. IDegAsp in individuals with type 2 diabetes
Background: This study aimed to evaluate the long-term cost-effectiveness of insulin glargine/lixisenatide injection (iGlarLixi) vs. insulin degludec/insulin aspart (IDegAsp) in individuals with poorly controlled type 2 diabetes in China. Methods: This study employed the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes model to simulate 20-year clinical and economic outcomes from the perspective of the Chinese healthcare sy…
The Impact of Reimbursement for Non–Face-to-Face Chronic Care Management on Comprehensive Metabolic Biomarkers Among Multimorbid Patients With Type 2 Diabetes
AIMS: We evaluated the impact of reimbursement for non-face-to-face chronic care management (NFFCCM) on comprehensive metabolic risk factors among multimorbid Medicare beneficiaries with type 2 diabetes in Louisiana. MATERIALS AND METHODS: We implemented a propensity score method to obtain comparable treatment (n=1501 with NFFCCM) and control (n=17,524 without NFFCCM) groups. Patients with type 2 diabetes were extracted from the electronic health…
No prominent works on this page.
The Impact of Reimbursement for Non–Face-to-Face Chronic Care Management on Comprehensive Metabolic Biomarkers Among Multimorbid Patients With Type 2 Diabetes
AIMS: We evaluated the impact of reimbursement for non-face-to-face chronic care management (NFFCCM) on comprehensive metabolic risk factors among multimorbid Medicare beneficiaries with type 2 diabetes in Louisiana. MATERIALS AND METHODS: We implemented a propensity score method to obtain comparable treatment (n=1501 with NFFCCM) and control (n=17,524 without NFFCCM) groups. Patients with type 2 diabetes were extracted from the electronic health…
Cost-effectiveness of iGlarLixi vs. IDegAsp in individuals with type 2 diabetes
Background: This study aimed to evaluate the long-term cost-effectiveness of insulin glargine/lixisenatide injection (iGlarLixi) vs. insulin degludec/insulin aspart (IDegAsp) in individuals with poorly controlled type 2 diabetes in China. Methods: This study employed the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes model to simulate 20-year clinical and economic outcomes from the perspective of the Chinese healthcare sy…
Diabetes mellitus (2 works) · Diabetes Treatment and Management (2 works) · Health care (2 works) · Type 2 diabetes (2 works) · Blood pressure (1 works) · Body mass index (1 works) · Chronic Disease Management Strategies (1 works) · Clinical trial (1 works) · Cohort (1 works) · Diabetes Management and Education (1 works)